Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.59 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139580 | 1.00 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4TACR1KCNH2 | |
| SCHEMBL11111638 | 0.86 | SLC6A3 (0.72) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11092197 | 0.86 | SLC6A3 (0.72) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11095084 | 0.83 | SLC6A3 (0.58) | SLC6A3SLC6A2SLC6A4TACR1KCNH2 | |
| SCHEMBL11084872 | 0.74 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL20149028 | 0.74 | KDM1A (0.45) | SLC6A3SLC6A2SLC6A4TACR1KCNH2 | |
| SCHEMBL11084875 | 0.74 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11084869 | 0.74 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL20149036 | 0.74 | KDM1A (0.45) | SLC6A3SLC6A2SLC6A4TACR1KCNH2 | |
| SCHEMBL11089310 | 0.71 | SLC6A3 (0.68) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3538522-A1 | ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089406-A1 | ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | RORB, RORC, RORA | SLC6A3 4614/4885SLC6A2 4360/4885SLC6A4 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.